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Abstract Recent studies have reported that human mutations
in Nav1.5 predispose to early age onset atrial arrhythmia. The
present experiments accordingly assess atrial arrhythmoge-
nicity in aging Scn5a+/ΔK P Qm i c em o d e l i n gl o n gQ T 3
syndrome in relationship to cardiac Na
+ channel, Nav1.5,
expression. Atrial electrophysiological properties in isolated
Langendorff-perfused hearts from 3- and 12-month-old wild
type (WT), and Scn5a+/ΔKPQ mice were assessed using
programmed electrical stimulation and their Nav1.5 expres-
sion assessed by Western blot. Cardiac conduction properties
were assessed electrocardiographically in intact anesthetized
animals. Monophasic action potential recordings demonstrat-
ed increased atrial arrhythmogenicity specifically in aged
Scn5a+/ΔKPQ hearts. These showed greater action potential
duration/refractory period ratios but lower atrial Nav1.5
expression levels than aged WT mice. Atrial Nav1.5 levels
were higher in young Scn5a+/ΔKPQ than young WT. These
levels increased with age in WT but not Scn5a+/ΔKPQ.
Both young and aged Scn5a+/ΔKPQ mice showed lower
heart rates and longer PR intervals than their WT counter-
parts. Young Scn5a+/ΔKPQ mice showed longer QT and
QTc intervals than young WT. Aged Scn5a+/ΔKPQ showed
longer QRS durations than aged WT. PR intervals were
prolonged and QT intervals were shortened in young relative
to aged WT. In contrast, ECG parameters were similar
between young and aged Scn5a+/ΔKPQ. Aged murine
Scn5a+/ΔKPQ hearts thus exhibit an increased atrial
arrhythmogenicity. The differing Nav1.5 expression and
electrocardiographic indicators of slowed cardiac conduction
between Scn5a+/ΔKPQ and WT, which show further
variations associated with aging, may contribute toward
atrial arrhythmia in aged Scn5a+/ΔKPQ hearts.
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Introduction
Atrial arrhythmia, of which the most common form is
atrial fibrillation (AF), is particularly common in the
elderly. Genetically normal patients show a median age
of onset of AF of 75 years with ∼70% of such patients
aged between 65 and 85 years [13]. There have been
recent studies implicating an involvement of cardiac ion
channels in the development of AF [5–7]. Thus, long QT
syndrome (LQTS) patients show an earlier than normal
onset of AF [20], typically at age ∼50±14 years [9]. In
particular, variants of the SCN5A gene encoding the
cardiac Na
+ channel (Nav1.5) have been clinically
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DOI 10.1007/s00424-010-0851-zassociated with the presence of AF. A study resequencing
the SCN5A coding regions reported that 6% of 375
patients with AF showed variations in SCN5A [9]. Roles
for Nav1.5 in the development of atrial arrhythmia are
further implicated by the SCN5A polymorphism, H558R,
prevalent in 20% of the population, also being a risk factor
for AF [8].
Of the >200 such SCN5A mutations reported [40], the
gain of function mutation Scn5a+/ΔKPQ involves deletion
of the three conserved amino acids, KPQ1505–1507. It has
been clinically associated with long QT syndrome type 3
(LQT3). This in turn is associated with a potentially fatal
ventricular arrhythmogenic tendency that increases with age
and that becomes evident within the first four decades of
life [50, 51]. Loss of function mutations in SCN5A are
associated with Brugada syndrome (BrS), a cardiac disorder
characterized by an elevated ST segment in electrocardio-
graphic (ECG) waveform [18]. Furthermore, a proportion
of patients that harbor various losses and gain of function
SCN5A mutations all demonstrate AF. Thus, 10–30% of
BrS patients show increased propensities to atrial fibrilla-
tion [4, 26, 31, 32]. In contrast, Benito et al. [3] described a
family, with eight members across three generations,
showing both early onset AF and LQT3 associated with a
mutant SCN5A gene involving the Y1795C mutation.
Similarly, early onset AF in a Japanese family has been
related to a novel gain-of-function, M1875T, mutation in
SCN5A [45].
Such similarities in clinical outcome as a result of
differing SCN5A mutations are consistent with reports of
overlap syndrome in patients with LQT3 and BrS;
conversely, some mutations can be associated with more
than one phenotype in particular patients [42, 45]. For
example, a single Na
+ channel mutation involving deletion
of lysine 1500, ΔK1500, is associated with not only LQTS
but also BrS and conduction system disease [16]. Also the
insertion D1795 induces both LQTS and BrS and has been
shown to result in a 62% reduction of channel expression
[2]. Finally, clinical phenotypes that overlap with those
observed in BrS have also been reported to occur in patients
carrying the SCN5A+/ΔKPQ mutation [35].
The physiological relationships between the underlying
SCN5A+/ΔKPQ mutation and such related ventricular
arrhythmic phenotypes have been investigated using a
murine Scn5a+/ΔKPQ model [44]. Murine systems have
also been used to study atrial arrhythmogenicity [25, 48].
However, very few experimental studies have related SCN5A
mutations to alterations in atrial arrhythmogenicity. One such
report described a reduced atrial arrhythmogenicity in Scn5a
+/ΔKPQ murine hearts modeling LQT3 syndrome [10].
However, it did not investigate the effects of aging.
Nevertheless, this is an important factor contributing to the
variable penetrance of LQT3 [15].
This study accordingly proceeds to explore for the
development of atrial arrhythmogenic properties with
aging, comparing these to action potential waveform and
refractory periods, Nav1.5 expression, and electrocardio-
graphic properties in Scn5a+/ΔKPQ and WT mice for the
first time. We demonstrated that Nav1.5 protein expression
was affected by age and genotype in a manner that would
be compatible with a phenotypic overlap and attributed
these findings to evidence for a compromised Nav1.5
function.
Methods
Experimental animals Wild-type (WT) and Scn5a+/ΔKPQ
mice, with an inbred 129/Sv genetic background, were
housed in cages at 21±1°C with 12 h light/dark cycles. The
mice, studied at ages of either 3 months (young) and
12 months (aged), were killed by cervical dislocation, in
compliance with the UK Animals (Scientific Procedures)
Act 1986.
Isolation, cannulation, and perfusion of mouse hearts For the
purpose of Na
+ channel extraction and experiments on
isolated Langendorff preparations, hearts were excised and
immediately placed in ice-cold bicarbonate Krebs–Henseleit
(KH) buffer solution containing (mM): 119 NaCl, 25 NaHCO3,
4.0 KCl, 1.2 KH2PO4,1 . 0M g C l 2, 1.8 CaCl2,1 0g l u c o s e ,a n d
2.0 sodium pyruvate (pH 7.4). The KH buffer was bubbled
with 95% O2/5% CO2 (British Oxygen Company, Man-
chester, UK) for 20 min prior to addition of 1.8 mM CaCl2.
The bubbling with 95% O2/5% CO2 was continued during the
experiments themselves. A 2-mm length of the aorta was
cannulated and held in place with an aneurysm clip. The
hearts were perfused with KH buffer warmed to 37°C until
they regained a healthy pink appearance and resumed
spontaneous activity. Perfusion was continued for a further
10 min before either electrophysiological studies or protein
extraction.
Monophasic action potential recording Hearts were ex-
cised and cannulated as described above, and AV nodes
were ablated. Left atrial monophasic action potentials
(MAPs) were recorded using a miniaturized MAP electrode
tip (Linton Instruments, Harvard Apparatus, UK). A
platinum stimulating electrode (1 mm inter-pole spacing)
was placed on the right atrium. Square wave stimuli (Grass
S48 stimulator, Grass-Telefactor, Slough, UK) of 2 ms
duration and ×1.5 threshold were applied at a cycle length
of 125 ms for 10 min until MAP waveforms had stable
baselines, rapid upstroke phases, and smooth repolarization
phases. Action potential durations were determined from
regular pacing. Programmed electrical stimulation (PES)
594 Pflugers Arch - Eur J Physiol (2010) 460:593–601was used to assess arrhythmogenicity and refractoriness.
This consisted of cycles of stimulus trains of eight S1 beats
delivered at 8 Hz at ×1.5 threshold followed by an S2
extrastimulus, at progressively shorter S1S2 coupling
intervals until the S2 no longer elicited an action potential.
Arrhythmia was defined as three or more consecutive
premature atrial waveforms.
Nav1.5 protein preparation After perfusion, left atrial
appendages were removed and clamp-frozen. The tissue
was homogenized in liquid nitrogen with a mortar and
pestle on dry ice. Homogenates were resuspended in a
solution consisting of (in mM) 50 Tris–HCl, 10 NaCl, 320
sucrose, 5 EDTA, and 2.5 EGTA (pH 7.4) and placed into
Eppendorf tubes and gently resuspended with a pipette tip.
Once thawed, but when still cool, the samples were placed
on ice. Samples were blade homogenized for 20 s each,
rinsing the blade thoroughly between samples. The
preparation was lysed with 1% Triton X100 and rotated
for 1 h at 4°C. After incubation, the samples were
subjected to centrifugation at 12,000×g and 4°C. The
supernatant was decanted into a sample loading buffer
(NuPAGE, Invitrogen, Paisley, UK) to obtain a 1:4
dilution. Samples were boiled at 70°C for 10 min, flash
frozen and stored at −80°C.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
and Western blots Five micrograms of total protein was
loaded per lane (NuPAGE gels) as was measured in
triplicate with Bradford Assay (Bio-Rad Laboratories Ltd,
Herts, UK) alongside a molecular weight marker (SeeBlue
Plus prestained standard, Paisley, UK). Duplicate gels were
subjected to Imperial Blue Protein stain (Thermo Scientific,
Rockford, IL, USA) to confirm equal loading. NuPAGE
electrophoresis tanks were used to run sodium dodecyl
sulfate polyacrylamide gel electrophoresis at 100 mA for
3 h. Protein bands were transferred onto nitrocellulose
membrane by a NuPAGE blotting system for 2 h. Mem-
branes were blocked overnight in 5% milk–Tris-buffered
saline–1% Tween, followed by several rinses prior to
incubation with Nav1.5 antibody (1:500, ASC005, Caltag
Medisystems, Alomone, Israel). The membranes were
incubated with secondary antibody conjugated with horse-
radish peroxidase from Sigma-Aldrich (Poole, Dorset, UK)
and rinsed five times. Western blot development was
performed with Amersham ECL reagents (Amersham
Biosciences, Amersham, Bucks, UK).
Electrophysiological study Mice were anesthetized with
Avertin (Sigma) 240 mg/kg at a dose rate of 0.1 ml/10 g
body weight. Injection was given intraperitoneally with a
27G hypodermic needle into the left peritoneal cavity. Lead
II ECG recordings were acquired using LabChart software
(ADI Instruments, Chalgrove, Oxfordshire, UK). This
incorporated algorithms for determinations of ECG param-
eters, including RR intervals, P wave durations, PR
intervals, QRS intervals and QT durations. It also included
QTc intervals derived from the QT interval corrected for
variations in the RR interval [19, 33]
Data analysis and statistics Datawasacquiredusingamodel
1401 interface, analysed with Spike version 5.2 (Cambridge
Electronic Design, Cambridge, UK) and are presented as
means ± standard errors of the means. Image J was used for
densitometry (NIH, Bethesda, MD, USA). Comparisons were
performed by a one-way analysis of variance (ANOVA) or
Fisher’s exact test where appropriate, with SPSS software
(SPSSUK,Woking,Surrey,UK).Foralltests,youngandaged
mice of the same genotype were compared followed by tests
between WT and Scn5a+/ΔKPQ of the same age. Statistical
significance was assumed at P<0.05.
Results
The Scn5a+/ΔKPQ mutation abolishes normal increases
in atrial refractory periods with age and results in high
action potential duration/atrial effective refractory period
(APD/AERP) ratios
Figure 1 shows representative traces of atrial MAPs from
young (3 months old) WT (a), young Scn5a+/ΔKPQ (b),
aged (12 month) WT (c), and aged Scn5a+/ΔKPQ (d) atria,
which show fast upstroke and smooth repolarization phases.
APDs were measured from the interval between upstroke
ab
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Aged WT  Aged Scn5a+/ΔKPQ
Fig. 1 Atrial monophasic action potentials (MAPs). Representative
tracesofhearts young(3monthsold)WT(a), young Scn5a+/ΔKPQ (b),
aged (12 month) WT (c)a n da g e dScn5a+/ΔKPQ (d)p a c e da t8H z
Pflugers Arch - Eur J Physiol (2010) 460:593–601 595peak and 90% repolarization. WT and Scn5a+/ΔKPQ atrial
preparations showed similar action potential durations
(Fig. 2a). Thus, there were no significant differences in
APD between young and aged hearts of the same genotype
or between WT and Scn5a+/ΔKPQ hearts of the same age.
Figure 2b demonstrates that the AERP was prolonged in
aged WT compared to young WT (P<0.001), consistent
with previous findings in murine hearts that atrial refractory
periods increase with advancing age. This would be
expected to offset any arrhythmogenic effects of
corresponding decreases in conduction velocity known to
occur with age [22, 23, 30]. In contrast, young and aged
Scn5a+/ΔKPQ atria showed similar AERPs. Young WT
and young Scn5a+/ΔKPQ hearts showed indistinguishable
AERPs. However, AERPs in aged WT hearts were
significantly prolonged compared to aged Scn5a+/ΔKPQ
(P<0.01; n=7 in each group).
Figure 2c summarizes APD/AERP ratios, previously
used to assess atrial arrhythmogenicity [10], derived from
the APD and AERP findings summarized above. Young
Scn5a+/ΔKPQ hearts showed increased APD/AERP ra-
tios compared to young WT hearts (P<0.05). However,
whereas APD/AERP ratios decreased with age in WT (P<
0.01), these remained the same in Scn5a+/ΔKPQ hearts,
with values approaching unity and significantly high ratios
in aged Scn5a+/ΔK P Qr e l a t i v et oa g e dW T( P<0.001).
This was consistent with the increased arrhythmic tenden-
c yf o u n ds p e c i f i c a l l yi na g e dScn5a+/ΔKPQ observed in
the experiments that followed.
Significant increases in atrial arrhythmogenic tendency
are specific to aged Scn5a+/ΔKPQ mice
The presence or otherwise as well as the frequency of
arrhythmic tendency in both WT and Scn5a+/ΔKPQ atrial
preparations were compared using PES in isolated heart
Langendorff-perfused hearts. The latter involved imposi-
tions of extrasystolic S2 stimuli at the end of trains of eight
pacing S1 stimuli. The S1 stimuli were delivered at 8 Hz,
and the S2 stimuli were delivered at S1S2 intervals that
were progressively decremented by 1 ms with each
successive pacing cycle. The protocols were terminated
when hearts either became refractory or went into self-
terminating arrhythmias. Figure 3a shows typical results
from an aged Scn5a+/ΔKPQ heart in the course of such a
procedure. Figure 3b exemplifies typical action potentials at
the end of such a procedure showing refractoriness
(arrowed). Figure 3c shows episodes of arrhythmias
(arrowed).
Table 1 summarizes the results of such experiments in
which the observed incidences of atrial arrhythmia in young
and aged, WT and Scn5a+/ΔKPQ hearts were compared
using Fisher's exact tests, assuming significance with P<
0.05. It demonstrates that both young and aged WT hearts
did not show significant incidences of arrhythmia. Similar-
ly, both young WT and young Scn5a+/ΔKPQ showed
indistinguishable incidences of arrhythmogenesis. In con-
trast, aged Scn5a+/ΔKPQ hearts showed significantly
greater incidences of arrhythmia compared to both young
Scn5a+/ΔKPQ (P<0.001) and aged WT (P<0.001).
The Scn5a+/ΔKPQ mutation results in abnormal changes
in Na
+ channel expression levels with age
Expression levels of the cardiac Na
+ channel, Nav1.5, from
atria of young and aged WT and Scn5a+/ΔKPQ mice were
examined by Western blotting of randomized blinded
samples. Nav1.5 was extracted from WT and Scn5a+/
ΔKPQ hearts, and Western blots were performed with 5 μg
of total protein per lane. Figure 4a shows blots of Nav1.5
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Fig. 2 Action potential durations (APDs) and atrial effective
refractory periods (AERPS) (a) APD90 values of young WT, young
Scn5a+/ΔKPQ, aged WT, and aged Scn5a+/ΔKPQ atria. b The effect
of age and Scn5a+/ΔKPQ mutation on AERPs in WT and Scn5a+/
ΔKPQ hearts. c Mean APD90/AERP ratios in WT and Scn5a+/ΔKPQ
hearts. The symbols *, †, and # indicate significant differences
between young WT and aged WT (*), young Scn5a+/ΔKPQ
compared to young WT (†) and aged Scn5a+/ΔKPQ compared to
aged WT (#) respectively. The notation *, †, and # denote P<0.05; **,
††, and ## denote P<0.01; and ***, †††, and ### denote P<0.001
596 Pflugers Arch - Eur J Physiol (2010) 460:593–601obtained from atrial tissue of the young WT (labeled +/+;
n=3) and Scn5a+/ΔKPQ hearts (labeled +/k; n=4 respec-
tively). Figure 4b shows antibody specific binding to
murine Nav1.5 from aged WT (n=4) and Scn5a+/ΔKPQ
(n=4) hearts. Figure 4c shows the results of densitometric
analysis that provided a relative quantification of Nav1.5.
The young WT mice showed lower levels of Nav1.5
expression than did the aged WT, indicating increases in
expression with aging (P<0.01). In contrast, both young
and aged Scn5a+/ΔKPQ atria contained similar levels of
Nav1.5. Comparisons between genotypes similarly demon-
strated that young Scn5a+/ΔKPQ mice showed higher
Nav1.5 expression than did young WT (P<0.05). Con-
versely, aged Scn5a+/ΔKPQ atria showed decreased
Nav1.5 expression compared to aged WT (P<0.05). Thus,
Scn5a+/ΔKPQ atria failed to show the age dependent
expression patterns demonstrated in WT mice.
Scn5a+/ΔKPQ hearts show altered conduction properties
Figure 5 shows typical results from experiments that
compared in vivo ECG features of WT and Scn5a+/ΔKPQ
hearts in intact mice anesthetized with Avertin. Each
recording period followed a 10-min period permitting the
preparation to stabilize and lasted 5 min. The PQRST
complexes in the lead II ECG readings confirmed normal
sequences of atrial activation and conduction, atrioven-
tricular (AV) conduction and ventricular depolarization as
well as recovery in all hearts whether in young (a) or aged
WT (b), or young (c) or aged Scn5a+/ΔKPQ (d). No
spontaneous arrhythmia was observed in any of the ECG
recordings.
Table 2 summarizes differences in electrocardiographic
parameters and therefore in cardiac pacing and conduction
function, expressed as means ± SEMs, between the different
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Fig. 4 Cardiac Na
+ channel, Nav1.5, expression. Western blots of
Nav1.5 obtained from atrial tissue of young (3 months) WT (labeled
+/+) and Scn5a+/ΔKPQ hearts (labeled +/k) (n=3 and 4, respective-
ly). Five micrograms of total protein was loaded per lane (a). Anti-
Nav1.5 antibody specific binding to samples from aged (12 months)
WT (n=4) and Scn5a+/ΔKPQ (n=4) hearts (b). Densitometric
analysis demonstrates that the Scn5a+/ΔKPQ mutation results in a
loss of the normal aging pattern showed by WT (c). The symbols *, †,
and # indicate significant differences between young WT and aged
WT (*), young Scn5a+/ΔKPQ compared to young WT (†), and aged
Scn5a+/ΔKPQ compared to aged WT (#) respectively. The notation *,
†, and # denote P<0.05; **, ††, and ## denote P<0.01; and ***, †††,
and ### denote P<0.001
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Fig. 3 Assessment for arrhythmogenicity during S1S2 pacing of the
left atria. A representative trace from an aged Scn5a+/ΔKPQ heart,
paced at 8 Hz (S1), delivered at ×1.5 threshold (a). An example of
atrial refractoriness with programmed electrical stimulation (PES).
The extrastimuli (S2) are delivered following a train of eight S1
stimuli at progressively shorter S1S2 coupling intervals until the S2 no
longer elicits an action potential (arrowed). The short lines below the
traces indicate S1 timings, and the longer lines indicate S2 stimuli (b).
Arrhythmic episode during PES (arrowed)( c)
Table 1 Incidence of atrial arrhythmia
WT Scn5a+/ΔKPQ
Young 3 of 7
c 0o f6
a
Aged 0 of 7
b 6o f6
a,b,c
Numbers of hearts that showed arrhythmic episodes when subjected to
PES at 8 Hz. The superscripted letters indicate significant differences
obtained from successive pairwise tests P<0.05
Pflugers Arch - Eur J Physiol (2010) 460:593–601 597murine populations examined. It also summarizes the results
of ANOVA tests of the electrocardiographic parameters,
sorted by the single variables of genotype and age. This was
followed by statistical tests for significant differences when
these findings were sorted by both these variables. These
demonstrated the following differences in pacemaker func-
tion and intracardiac conduction that corroborated the present
findings, extending some of them to ventricular properties of
the heart. Thus, (1) the Scn5a+/ΔKPQ mutation results in an
inhibited SA node function. Thus, RR intervals were greater
in young Scn5a+/ΔKPQ compared to young WT mice and
aged Scn5a+/ΔKPQ compared to the aged WT mice. (2)
Scn5a+/ΔKPQ and WT mice showed similar action poten-
tial durations as reflected in their P wave durations in
agreement with MAP results. (3) AV conduction as assessed
by PR intervals was consistently slower in Scn5a+/ΔKPQ
than WT, when comparisons were made by age. It was also
slower in aged Scn5a+/ΔKPQ compared to aged WT. (4)
Intraventricular conduction, reflected in QRS intervals, was
prolonged in the aged Scn5a+/ΔKPQ compared to aged WT
but was similar between young Scn5a+/ΔKPQ and young
WT. Finally, (5) ventricular action potential durations,
assessed by QT intervals and QTc intervals, were longer in
the young Scn5a+/ΔKPQ compared to the young WT
hearts. Such intervals were similar between young and aged
Scn5a+/ΔKPQ but increased with age in WT.
Discussion
The present experiments compared changes in basic electro-
physiological properties and their relationship to the develop-
mentorotherwise ofatrialarrhythmogenicpropertiesinaging
murineScn5a+/ΔKPQ and WT hearts. They extend previous
reports on atrial [10] and ventricular [41, 44]a r r h y t h m o g e -
nicity in Scn5a+/ΔKPQ hearts that, however, did not explore
effects of aging on these properties. An initial determination
of the normal changes in WT provided controls against
which to assess the presence or absence of abnormal changes
in the Scn5a+/ΔKPQ hearts. MAP records were first
obtained from Langendorff-perfused hearts to explore for
arrhythmogenic properties in response to both regular and
extrasystolic imposed stimulation. These properties were
then compared with the features of action potential recovery
as reflected in their durations and refractory periods. The
presence or absence of arrhythmogenicity was then related to
the results of Western blot determinations of cardiac Na
+
channel (Nav1.5) expression levels performed for the first
time in the Scn5a+/ΔKPQ system. These in turn were
related to electrocardiographic assessments of in vivo cardiac
conduction properties in anesthetized animals.
The MAP studies in isolated Langendorff-perfused
hearts assessed the frequencies of atrial arrhythmogenesis
in young and aged, WT and Scn5a+/ΔKPQ, hearts using a
PES procedure. They demonstrated for the first time that
aged Scn5a+/ΔKPQ hearts showed an increased atrial
arrhythmogenicity compared to any of the other three
groups. This took place despite an absence of any
detectable differences in atrial action potential durations to
90% recovery (APD). The latter finding rules out arrhyth-
Young WT  Young Scn5a+/ΔKPQ 
ab
c d
Aged WT  Aged Scn5a+/ΔKPQ 
130 ms
Fig. 5 Representative ECG recordings from young WT (a), young
Scn5a+/ΔKPQ (b), aged WT (c), and aged Scn5a+/ΔKPQ (d) hearts
respectively
Table 2 ECG parameters compared in WT and Scn5a+/ΔKPQ
WT Scn5a+/ΔKPQ
Young Aged Young Aged
RR interval, ms 141.18±3.03 (6)
a 129.87±4.49 (5)
b 161.12±1.32 (5)
a 152.54±8.18 (6)
b
Heart rate 426.51±8.73 (6)
c 464.54±16.73 (5)
d 372.75±3.05 (5)
c 399.03±20.71 (6)
d
PR interval (ms) 45.00±1.93 (5)
e,f 37.31±1.92 (6)
e,g 50.45±0.83 (5)
f 48.09±1.46 (6)
g
P wave duration (ms) 11.40±0.77 (6) 13.42±1.19 (5) 16.59±2.60 (5) 15.74±1.50 (6)
QRS interval (ms) 11.48±0.93 (6) 10.75±0.24 (5)
h 12.88±0.68 (5) 15.70±1.91 (6)
h
QT interval (ms) 33.03±1.44 (6)
i,j 44.08±9.79 (5)
i 45.89±2.49 (5)
j 47.81±2.79 (6)
QTc interval (ms) 27.95±1.40 (6)
k,l 37.56±4.07 (5)
k 37.31±1.45 (5)
l 38.83±2.21 (6)
The superscripts a–l indicate significant differences between the designated values (P<0.05; n values given in parenthesis)
598 Pflugers Arch - Eur J Physiol (2010) 460:593–601mogenic mechanisms involving action potential recovery
previously implicated in the ventricular arrhythmogenicity
shown by Scn5a+/ΔKPQ on earlier occasions [46].
Whereas refractory periods in young WT and young
Scn5a+/ΔKPQ were closely similar, they sharply increased
with age in WT, consistent with previous reports [23];
however, they did not do so in Scn5a+/ΔKPQ. Conse-
quently, Scn5a+/ΔKPQ hearts showed shorter refractory
periods and greater APD/AERP ratios than aged WT. Both
of these have been previously introduced as indices of
ventricular [41] as well as atrial [10] arrhythmogenicity,
respectively. These results were thus consistent with the
higher inducibility of atrial arrhythmias by programmed
atrial stimulation that was observed in aged Scn5a/ΔKPQ
mice.
These findings were then compared with results from
complementary examinations of Nav1.5 protein expression in
the experimental groups. Such Western blot studies directly
measure specific protein levels as opposed to indirect
measures involving messenger RNA (mRNA). These demon-
strated that Nav1.5 channel expression increased with age and
genotype, complementing previous electrophysiological
reports of altered cardiac Ca
2+ and K
+ channel expression
with age in WT [11, 21]. Thus, young WT showed relatively
low levels of Nav1.5 expression, but these markedly
increased with normal aging. In contrast, young Scn5a+/
ΔKPQ showed higher Nav1.5 expression than young WT
but then showed no further increases with age. Aged Scn5a+/
ΔKPQ consequently showed substantially lower Nav1.5
expression than aged WT.
The latter findings were compatible with the final,
electrocardiographic, results. These similarly revealed
genotype- and age-specific phenotypic alterations in intact
anesthetized WT and Scn5a+/ΔKPQ mice. Firstly, young
Scn5a+/ΔKPQ mice showed longer QT and QTc intervals
than did young WT, consistent with the LQT3 condition.
Secondly, even young WT and young Scn5a+/ΔKPQ mice
differed in those ECG features that bore on atrial pacemaker
and AV conduction properties. Young and aged Scn5a+/
ΔKPQ mice had lower heart rates and slower AV
conduction than their respective WT counterparts. In
addition, aged Scn5a+/ΔKPQ mice showed depressed
intra-ventricular conduction relative to aged WT. Finally,
WT and Scn5a+/ΔKPQ also showed differing alterations
with age. Thus, while PR and QT intervals change with age
in WT mice, this was not evident in Scn5a+/ΔKPQ hearts.
Comparisons between these findings were consistent
with a hypothesis in which small APD/AERP ratios
together with high levels of Nav1.5 expression might
balance the arrhythmic effects of a slowing of conduction
with age. This could be related to a progressive interstitial
fibrosis that has been shown to occur in the atria of humans
[12, 43] and animals [1, 17]; the latter includes mice with
mutations involving Scn5a [39]. Such fibrosis is also
associated with clinical AF [24, 29]. In addition, localized
alterations in AERP shown to increase with age would be
expected to accentuate dispersions of intra-atrial refractori-
ness [49]. All these processes would be expected to cause a
heterogeneous slowing of atrial conduction and consequent
age-related increases in atrial arrhythmic tendency.
In such a situation, the observed increases in Nav1.5 could
protect against atrial arrhythmia in aged WT. Thus, WT hearts
were not arrhythmogenic: APD/AERP ratios were smaller for
aged WT than young WT, while there was a higher Nav1.5
expressioninagedWTrelativetoyoungWT.Incontrast,aged
Scn5a+/ΔKPQ were more arrhythmogenic than the remain-
ing groups. This was consistent with their higher APD/
AERP ratios and reduced Nav1.5 expression levels relative
to aged WT. Finally, these results additionally relate the
greater arrhythmogenecity of aged Scn5a+/ΔKPQ compared
to young Scn5a+/ΔKPQ, despite similar APD/AERP ratios
and AERP values, to their failure to increase Nav1.5
expression with age unlike WT. Thus, despite possessing a
gain of function mutation, aged Scn5a+/ΔKPQ atria showed
reduced Nav1.5 expression levels and high APD/AERP
ratios. This may have resulted in an atrial arrhythmogenicity
that was prevented by the increase in Nav1.5 expression with
age shown by the WT.
Such changes could also involve altered expression of a
range of genes and ion channels, besides Nav1.5. Thus,
ventricular mRNA expression profiles in studies of human
BrS associated with Na
+ channelopathy suggested remod-
eled K
+ and Ca
2+ in addition to Na
+-channel expression
[14]. For example, their reduced expression of Kv4.3
encoding the principal Ito subunit, increased transcript
expression of Nav2.1, and increased 2P-channel expression
would tend to compensate for the Nav1.5 underexpression
observed in BrS-affected individuals. Conditions of atrial
fibrillation or tachycardia results in reductions of transient
outward K
+ current (Ito), downregulation of ICaL pore-
forming α-subunit mRNA, and increased expression of
Kir2.1 mRNA and protein [36]. Furthermore, there is
evidence associating BrS with such atrial remodeling [47].
In demonstrating that aged Scn5a+/ΔKPQ mice show an
increased propensity to atrial arrhythmia, the findings in
this study thus recapitulate clinical situations of phenotypic
overlap between LQTS and BrS. A loss of Nav1.5 function
may reflect haploinsufficiency and impaired intracellular
trafficking reducing surface level expression [38]. The
reduction in Nav1.5 protein expression observed here is
compatible with such a possibility. This in turn may be the
cause of a situation resembling the case of the Brugada
mouse model in which a loss of Na
+ channel expression
results in both ventricular [37] and atrial arrhythmogenic
properties [27, 28]. Such a notion would be compatible
with the electrocardiographic evidence for reduced pace-
Pflugers Arch - Eur J Physiol (2010) 460:593–601 599maker activity and delayed conduction in both young and
aged Scn5a+/ΔKPQ relative to WT hearts. These also
parallel reduced SA node activity and slowed AV conduc-
tion that has been reported in BrS patients [34]. Taken
together, these findings could therefore account for pheno-
typic overlaps between LQT3 and BrS patients [42] besides
demonstrating the existence of a complex dynamic inter-
play between aging, ion channel expression, and cardiac
tissue excitability.
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